Please login to the form below
omalizumab
This page shows the latest omalizumab news and features for those working in and with pharma, biotech and healthcare.
FDA approves new self-injection administration for Xolair
The FDA has approved the biologics licence application (BLA) for Xolair(omalizumab) prefilled syringe for self-injection across all approved indications in the US.
Latest news
-
Novartis reveals positive efficacy data for Xolair follow-up
older immunology drug Xolair (omalizumab). .
-
China updates drug reimbursement list, agrees price cuts
The key drugs which have been added to the list include AbbVie’s blockbuster drug Humira (adalimumab), Novartis’ dermatitis drug Xolair (omalizumab) and Roche’s HER2 breast cancer treatment Perjeta (petuzumab).
-
FDA clears Dupixent as first-ever drug for chronic rhinosinusitis with nasal polyps
Roche and Novartis’ severe asthma therapy Xolair (omalizumab) has data showing it is effective as a treatment for polyps, but isn’t expected to be approved until the end of next
-
Novartis claims first place for psoriasis drug Cosentyx in China
The firm has recently picked up Chinese approvals for a clutch of therapies including Xolair (omalizumab) for asthma and heart failure therapy Entresto (valsartan/sacubitril).
-
FDA gives breakthrough status to Xolair for food allergies
The US regulator awarded Xolair (omalizumab) the coveted status for the prevention of severe allergic reactions following accidental exposure to one or more foods in people with allergies, opening up another
More from news
Approximately 7 fully matching, plus 22 partially matching documents found.
Latest from PMHub
-
RWE Blog 1: Real-world challenges and real-world data
A meta-analysis of real-world studies where omalizumab treatment of chronic idiopathic urticaria met or improved on both efficacy and safety predictions from the RCTs.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Account Manager - Creative Healthcare Comms - Immediat...
-
Excellent Day Rate
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Freelance Medical Writer - Creative Healthcare Comms - 2 month t...
-
Excellent Day Rate
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Content Editor - Biotechnology
-
Salary TBC
-
Account Management
-
Competitive Salary Offered
- AZ showcases data for next-generation PARP inhibitor AZD5305
- Sanofi pays $160m upfront to acquire Tidal Therapeutics
- GSK discontinues two feladilimab trials in head and neck cancer
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- Pfizer/BioNTech say their COVID-19 vaccine can be stored at warmer temperatures
- Virtual congresses: video thrilled the cardio tsar
- Lilly asks to revoke emergency authorisation for bamlanivimab monotherapy in the US
- CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval
- Alexion and NICE agree confidential discount for Ultomiris use on the NHS
- Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses
- Merck & Co halts development of potential COVID-19 drug MK-7110
- Virtually, the same: Is it time to rethink congress strategy?
PMHub
CSafe Global
CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...
Latest intelligence
- InSite Events™ National Pharma Meeting: A Customer Story
- How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
- Fear or encouragement, which is best to drive behaviour change?
- The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
- The unheard, unseen, and uncorrected effects of COVID-19
- The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...
Quick links
Infographics
